BWAY reports Q2 results this morning, with yesterday's preview article noting the tightening borrow picture — and that setup remains intact heading into the open.
The lending story is unchanged from yesterday's read. Availability has held at 111.7%, down roughly 27% on the week, and cost to borrow is running near 13.9% — a level that has barely moved in months, suggesting structural rather than event-driven demand for shorts. Shares available to lend remain at their 30-day low of around 137,000. The borrow is expensive and getting incrementally harder to source, but the market is not in squeeze territory. That combination — tight but not extreme — means short sellers are under mild pressure without being forced to act.
The insider selling thread from the prior article also holds. The CTO and founder/Chief Scientific Officer both trimmed positions through May and June, with the CSO executing four separate transactions across three days in early June. Net insider activity over the past 90 days reflects selling of around 41,400 shares, worth roughly $636,000. None of these were large enough to signal distress on their own, but the pattern is consistent: no insiders have bought ahead of this print. The short score has continued its quiet drift higher, reaching 49.4 from around 47.5 a week ago, while the DTC rank of 73 underlines that covering would take time if the print triggers a rush.
The print is therefore a test of whether BrainsWay's revenue growth — running at roughly 29% year-on-year as of the most recent score data — can sustain a valuation that has carried the stock up over 60% year-to-date, against a lending market that has grown incrementally more cautious with each passing session this week.
See the live data behind this article on ORTEX.
Open BWAY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
